Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Fas 3-studie av tilläggsbehandling med Seltorexant hos vuxna och äldre deltagare med allvarlig depressiv sjukdom och sömnlöshetssymtom

2 november 2026 uppdaterad av: Janssen Research & Development, LLC

En tvådelad multicenter, dubbelblind, randomiserad placebokontrollerad studie för att utvärdera effektivitet och säkerhet och bibehålla effekten av 20-(milligram) mg Seltorexant som tilläggsterapi till antidepressiva läkemedel hos vuxna och äldre patienter med allvarlig depressiv sjukdom med sömnlöshetssymtom

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

752

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Buenos Aires, Argentina, C1133AAH
        • Aktiv, inte rekryterande
        • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
      • Córdoba, Argentina, 5000FJF
        • Aktiv, inte rekryterande
        • CEN Consultorios Especializados en Neurociencias
      • Córdoba, Argentina, X5003DCE
        • Aktiv, inte rekryterande
        • Instituto Medico DAMIC
      • Córdoba, Argentina, X5006CBI
        • Aktiv, inte rekryterande
        • Centro Medico Luquez
      • Córdoba, Argentina, X5009BIN
        • Aktiv, inte rekryterande
        • Sanatorio Prof Leon S Morra S A
      • La Plata, Argentina, 1900
        • Aktiv, inte rekryterande
        • INSA Instituto de Neurociencias San Agustín
      • Rosario, Argentina, 2000
        • Aktiv, inte rekryterande
        • C I A P Centro de investigacion y Asistencia en Psiquiatria
      • Santiago del Estero, Argentina, 4200
        • Aktiv, inte rekryterande
        • Clinica El Jardin
      • Brasília, Brasilien, 70200 730
        • Avslutad
        • L2IP Instituto de Pesquisas Clinicas
      • Campinas, Brasilien, 13087 567
        • Aktiv, inte rekryterande
        • CAEP Centro Avancado De Estudos E Pesquisas
      • Criciúma, Brasilien, 88811 000
        • Aktiv, inte rekryterande
        • Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose
      • Natal, Brasilien, 59012 300
        • Avslutad
        • Universidade Federal do Rio Grande do Norte Hospital Universitario Onofre Lopes
      • Passo Fundo, Brasilien, 99010 120
        • Upphängd
        • Instituto Mederi de Pesquisa e Saude
      • Porto Alegre, Brasilien, 90619900
        • Avslutad
        • Uniao Brasileira de Educacao e Assistencia INSCER Instituto do Cerebro do Rio Grande do Sul
      • Porto Alegre, Brasilien, 90035 903
        • Avslutad
        • Hospital De Clinicas De Porto Alegre
      • Porto Alegre, Brasilien, 90430001
        • Aktiv, inte rekryterande
        • NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
      • Rio de Janeiro, Brasilien, 22270 060
        • Aktiv, inte rekryterande
        • Ruschel Medicina e Pesquisa Clínica Ltda
      • São Bernardo do Campo, Brasilien, 09726 150
        • Aktiv, inte rekryterande
        • Centro Integrado Facili
      • São Paulo, Brasilien, 01228 000
        • Aktiv, inte rekryterande
        • CPQuali Pesquisa Clinica LTDA ME
      • São Paulo, Brasilien, 01236030
        • Aktiv, inte rekryterande
        • BR Trials
      • Burgas, Bulgarien, 8001
        • Aktiv, inte rekryterande
        • Mental Health Center Prof. Dr. Ivan Temkov
      • Plovdiv, Bulgarien, 4002
        • Aktiv, inte rekryterande
        • UMHAT 'Sveti Georgi'- Plovdiv, Psychiatry Clinic
      • Sofia, Bulgarien, 1377
        • Avslutad
        • Centre for Mental Health Prof.N.Shipkovenski EOOD
      • Sofia, Bulgarien, 1113
        • Aktiv, inte rekryterande
        • Medical Center St. Naum
      • Sofia, Bulgarien, 1408
        • Aktiv, inte rekryterande
        • DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
      • Stara Zagora, Bulgarien, 6010
        • Avslutad
        • Medical Center ZaraMed
      • Varna, Bulgarien, 9020
        • Aktiv, inte rekryterande
        • Diagnostic Consulting Center Mladost - M Varna
      • Barranquilla, Colombia, 080002
        • Aktiv, inte rekryterande
        • Centro de Investigaciones y Proyectos en Neurociencias CIPNA
      • Bello, Colombia, 051053
        • Aktiv, inte rekryterande
        • HOMO - ESE Hospital Mental de Antioquia
      • Bogotá, Colombia, 111166
        • Avslutad
        • Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda.
      • Pereira, Colombia, 660001
        • Aktiv, inte rekryterande
        • Psynapsis Salud Mental S.A.
    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35294
        • Avslutad
        • University of Alabama at Birmingham
    • Arizona
      • Chandler, Arizona, Förenta staterna, 85224
        • Avslutad
        • Chandler Clinical Trials
      • Tucson, Arizona, Förenta staterna, 85724
        • Rekrytering
        • University of Arizona
    • Arkansas
      • Bryant, Arkansas, Förenta staterna, 72022
        • Rekrytering
        • SanRo Clinical Research Group LLC WCG Clinical Network
      • Little Rock, Arkansas, Förenta staterna, 72211
        • Avslutad
        • Preferred Research Partners
    • California
      • Anaheim, California, Förenta staterna, 92801
        • Rekrytering
        • PAMOJA Clinical Institute LLC
      • Colton, California, Förenta staterna, 92324
        • Rekrytering
        • Axiom Research
      • Encino, California, Förenta staterna, 91316
        • Avslutad
        • Elite Research Network 6
      • Glendale, California, Förenta staterna, 91206
        • Rekrytering
        • Behavioral Research Specialists LLC
      • Los Alamitos, California, Förenta staterna, 90720
        • Avslutad
        • WR PRI Los Alamitos
      • Oceanside, California, Förenta staterna, 92056
        • Rekrytering
        • Excell Research Inc
      • Rancho Cucamonga, California, Förenta staterna, 91730
        • Avslutad
        • Prospective Research Innovations Inc
      • Redlands, California, Förenta staterna, 92374
        • Rekrytering
        • Anderson Clinical Research
      • San Jose, California, Förenta staterna, 95124
        • Rekrytering
        • Lumos Clinical Research Center LLC
      • Santa Ana, California, Förenta staterna, 92705
        • Avslutad
        • Syrentis Clinical Research
      • Sherman Oaks, California, Förenta staterna, 91403
        • Avslutad
        • California Neuroscience Research
    • Colorado
      • Denver, Colorado, Förenta staterna, 80209
        • Rekrytering
        • Mountain View Clinical Research
    • Connecticut
      • Farmington, Connecticut, Förenta staterna, 06030
        • Rekrytering
        • UConn Health Center
    • Florida
      • Brandon, Florida, Förenta staterna, 33511
        • Rekrytering
        • Clinical Research of Brandon
      • Hialeah, Florida, Förenta staterna, 33012
        • Aktiv, inte rekryterande
        • AGA Clinical Trials
      • Hialeah, Florida, Förenta staterna, 33012
        • Aktiv, inte rekryterande
        • Reliable Clinical Research
      • Homestead, Florida, Förenta staterna, 33033
        • Aktiv, inte rekryterande
        • Advanced Research Institute of Miami
      • Jacksonville, Florida, Förenta staterna, 32256
        • Aktiv, inte rekryterande
        • Clinical NeuroScience Solutions Inc
      • Lake City, Florida, Förenta staterna, 32055
        • Avslutad
        • Multi Specialty Research Associates Inc
      • Largo, Florida, Förenta staterna, 33777
        • Avslutad
        • Alcanza Clinical Research
      • Miami, Florida, Förenta staterna, 33186
        • Rekrytering
        • Nuovida Research Center
      • Miami, Florida, Förenta staterna, 33126
        • Aktiv, inte rekryterande
        • Pharmax Research Clinic Inc
      • Miami, Florida, Förenta staterna, 33176
        • Aktiv, inte rekryterande
        • Miami Dade Medical Research Institute
      • Naples, Florida, Förenta staterna, 34105
        • Avslutad
        • Aqualane Clinical Research
      • North Bay Village, Florida, Förenta staterna, 33141
        • Avslutad
        • Bravo Health Care Center
      • Orlando, Florida, Förenta staterna, 32803
        • Aktiv, inte rekryterande
        • Nova Psychiatry INC
      • Saint Augustine, Florida, Förenta staterna, 32086
        • Avslutad
        • Florida Center for TMS
      • Tampa, Florida, Förenta staterna, 33613
        • Avslutad
        • University of South Florida
      • Tampa, Florida, Förenta staterna, 33629
        • Rekrytering
        • Interventional Psychiatry of Tampa Bay
      • Tampa, Florida, Förenta staterna, 33614
        • Rekrytering
        • Psych Me Medical Research Inc
      • West Palm Beach, Florida, Förenta staterna, 33407
        • Rekrytering
        • Health Synergy Clinical Research
      • Winter Park, Florida, Förenta staterna, 32789
        • Avslutad
        • Conquest Research
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30328
        • Rekrytering
        • Agile Clinical Research Trials, LLC
      • Atlanta, Georgia, Förenta staterna, 30318
        • Aktiv, inte rekryterande
        • Advanced Discovery Research
      • Decatur, Georgia, Förenta staterna, 30030
        • Aktiv, inte rekryterande
        • iResearch Atlanta LLC
      • Dunwoody, Georgia, Förenta staterna, 30338
        • Avslutad
        • Peachford Hospital-Atlanta Behavorial Research
      • Savannah, Georgia, Förenta staterna, 31405
        • Avslutad
        • iResearch Savannah
      • Snellville, Georgia, Förenta staterna, 30078
        • Avslutad
        • Renew Health Clinical Research
      • Snellville, Georgia, Förenta staterna, 30078
        • Avslutad
        • Accelerated Clinical Research Group LLC
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Rekrytering
        • Northwestern University
      • Chicago, Illinois, Förenta staterna, 60614
        • Avslutad
        • MetroMed Clinical Research
      • Chicago, Illinois, Förenta staterna, 60637
        • Avslutad
        • University of Chicago Medical Center
      • Elgin, Illinois, Förenta staterna, 60123
        • Avslutad
        • Revive Research Institute
      • Naperville, Illinois, Förenta staterna, 60563
        • Rekrytering
        • Baber Research Group
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02131
        • Avslutad
        • Boston Clinical Trials
      • Watertown, Massachusetts, Förenta staterna, 02472
        • Rekrytering
        • Adams Clinical LLC
    • Minnesota
      • Mankato, Minnesota, Förenta staterna, 56001
        • Avslutad
        • Mankato Clinic
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89121
        • Avslutad
        • Oasis Clinical Research LLC
      • Las Vegas, Nevada, Förenta staterna, 89119
        • Avslutad
        • Redbird Research
    • New Hampshire
      • Portsmouth, New Hampshire, Förenta staterna, 03801
        • Avslutad
        • ActivMed Practices and Research
    • New York
      • Brooklyn, New York, Förenta staterna, 11235
        • Rekrytering
        • SPRI Clinical Trials, LLC
      • Brooklyn, New York, Förenta staterna, 11229
        • Rekrytering
        • Integrative Clinical Trials LLC
      • Buffalo, New York, Förenta staterna, 14202
        • Avslutad
        • University at Buffalo Psychiatry
      • Mount Kisco, New York, Förenta staterna, 10549
        • Rekrytering
        • Bioscience Research LLC
      • New York, New York, Förenta staterna, 10017
        • Rekrytering
        • Fieve Clinical Research Inc
      • New York, New York, Förenta staterna, 10022
        • Avslutad
        • Hapworth Psychiatric Medical PLLC
      • Woodbury, New York, Förenta staterna, 11797
        • Avslutad
        • Lucian Miron Manu MD Psychiatry PC
    • North Carolina
      • Hickory, North Carolina, Förenta staterna, 28601
        • Avslutad
        • IMA Clinical Research PC 3
    • Ohio
      • Avon Lake, Ohio, Förenta staterna, 44012
        • Avslutad
        • Haidar Almhana Nieding
      • Cincinnati, Ohio, Förenta staterna, 45215
        • Rekrytering
        • Patient Priority Clinical Sites LLC
      • Cincinnati, Ohio, Förenta staterna, 45219
        • Avslutad
        • University of Cincinnati College of Medicine
      • Columbus, Ohio, Förenta staterna, 43210
        • Rekrytering
        • The Ohio State University
      • Middleburg Heights, Ohio, Förenta staterna, 44130
        • Avslutad
        • North Star Medical Research
    • Oklahoma
      • Edmond, Oklahoma, Förenta staterna, 73013
        • Rekrytering
        • Conrad Clinical Research
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Rekrytering
        • University of Pennsylvania
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Avslutad
        • Medical University of South Carolina
      • Charleston, South Carolina, Förenta staterna, 29406
        • Rekrytering
        • Clinical Trials of South Carolina
    • Texas
      • Austin, Texas, Förenta staterna, 78712
        • Avslutad
        • The University of Texas at Austin
      • Austin, Texas, Förenta staterna, 78759
        • Avslutad
        • BioBehavioral Research of Austin PC
      • Bellaire, Texas, Förenta staterna, 77401
        • Rekrytering
        • Houston Clinical Trials LLC
      • Dallas, Texas, Förenta staterna, 75243
        • Avslutad
        • Relaro Medical Trials
      • Fort Worth, Texas, Förenta staterna, 76104
        • Rekrytering
        • North Texas Clinical Trials
      • Garland, Texas, Förenta staterna, 75041
        • Avslutad
        • VAST Clinical Research
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • Baylor College of Medicine
      • Houston, Texas, Förenta staterna, 77081
        • Avslutad
        • DM Clinical Research
      • Stafford, Texas, Förenta staterna, 77477
        • Aktiv, inte rekryterande
        • R and H Clinical Research
      • Wichita Falls, Texas, Förenta staterna, 76309
        • Rekrytering
        • Grayline Research Center
    • Utah
      • Draper, Utah, Förenta staterna, 84020
        • Avslutad
        • Cedar Clinical Research
    • Washington
      • Everett, Washington, Förenta staterna, 98201
        • Rekrytering
        • Core Clinical Research
      • Brescia, Italien, 25123
        • Avslutad
        • Territorial Social Health Authority of the Spedali Civili of Brescia
      • Catania, Italien, 95123
        • Aktiv, inte rekryterande
        • Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
      • Chieti, Italien, 66100
        • Aktiv, inte rekryterande
        • Universita D Annunzio
      • Genova, Italien, 16132
        • Avslutad
        • IRCCS Aor San Martino IST
      • Monza, Italien, 20900
        • Avslutad
        • Fondazione IRCCS San Gerardo dei Tintori
      • Pisa, Italien, 56126
        • Avslutad
        • Azienda Ospedaliero Universitaria Pisana
      • Roma, Italien, 00168
        • Avslutad
        • Policlinico Universitario Agostino Gemelli
      • Roma, Italien, 00189
        • Aktiv, inte rekryterande
        • Azienda Ospedaliera Sant Andrea
      • Salerno, Italien, 84020
        • Avslutad
        • Ospedale S Francesco d Assisi
      • Siena, Italien, 53100
        • Aktiv, inte rekryterande
        • A O Universitaria Senese Ospedale Santa Maria alle Scotte
      • Mexico City, Mexiko, 04100
        • Rekrytering
        • Ketamine Mexico S de RL de C V
      • Mexico City, Mexiko, 07000
        • Rekrytering
        • Gabipros SC
      • Mexico City, Mexiko, 03100
        • Avslutad
        • Health Pharma Professional Research
      • Monterrey, Mexiko, 64710
        • Rekrytering
        • Instituto de Informacion e Investigacion en Salud Mental A.C.
      • Nuevo León, Mexiko, 64460
        • Rekrytering
        • Hospital Universitario Dr Jose Eleuterio Gonzalez
      • Nuevo León, Mexiko, 64620
        • Avslutad
        • Centro de Estudios Clinicos y Especialidades Medicas S C
      • San Luis de Potosi, Mexiko, 78218
        • Rekrytering
        • Hospital Lomas de San Luis Internacional
      • Bydgoszcz, Polen, 85-133
        • Rekrytering
        • PROMENTE Sp. z o.o.
      • Bydgoszcz, Polen, 85 794
        • Rekrytering
        • Osrodek Badan Klinicznych CLINSANTE S C Ewa Galczak Nowak Malgorzata Trzaska
      • Bydgoszcz, Polen, 85 605
        • Avslutad
        • Centrum Medyczne Intercor Sp z o o
      • Gdansk, Polen, 80 283
        • Rekrytering
        • Centrum Zdrowia Alcea
      • Gorlice, Polen, 30073
        • Avslutad
        • Specjalistyczna Praktyka Lekarska Piotr Zalitacz
      • Grudziądz, Polen, 86 300
        • Rekrytering
        • Przychodnie Grudziadz sp. z o.o.
      • Katowice, Polen, 40 514
        • Rekrytering
        • Clinic BBP Sp z o o
      • Leszno, Polen, 64-100
        • Rekrytering
        • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
      • Poznan, Polen, 60 192
        • Rekrytering
        • Praktyka Lekarska dr n med Malgorzata Wojtanowska Bogacka
      • Warsaw, Polen, 00-774
        • Rekrytering
        • Szpital Nowowiejski Osrodek Badan Klinicznych
      • Warsaw, Polen, 02-172
        • Avslutad
        • MTZ Clinical Research Powered by Pratia
      • Braga, Portugal, 4710 243
        • Avslutad
        • Uls Braga - Hosp. Braga
      • Leiria, Portugal, 2410 197
        • Avslutad
        • Uls Regiao Leiria - Hosp. Santo Andre
      • Lisbon, Portugal, 1649 035
        • Avslutad
        • Uls Santa Maria - Hosp. Santa Maria
      • Lisbon, Portugal, 1349 019
        • Avslutad
        • Uls Lisboa Ocidental - Hosp. Egas Moniz
      • Lisbon, Portugal, 1400 038
        • Aktiv, inte rekryterande
        • Fund. Champalimaud
      • Loures, Portugal, 2674 514
        • Aktiv, inte rekryterande
        • Uls Loures Odivelas - Hosp. Loures
      • Ponta Delgada, Portugal, 9500 370
        • Avslutad
        • Hosp. Divino Espirito Santo Ponta Delgada
      • Porto, Portugal, 4100 180
        • Aktiv, inte rekryterande
        • Hosp. Cuf Porto
      • Touguinho, Portugal, 4480-565
        • Avslutad
        • Hosp. Central Trofa Saude
      • Bucharest, Rumänien, 041914
        • Rekrytering
        • Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia
      • Bucharest, Rumänien, 041914
        • Avslutad
        • Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia 2
      • Cluj-Napoca, Rumänien, 400012
        • Avslutad
        • Spitalul Clinic Judetean de Urgenta Cluj Napoca
      • Cluj-Napoca, Rumänien, 400012
        • Avslutad
        • Spitalul Clinic Judetean de Urgenta Cluj Napoca 1
      • Craiova, Rumänien, 200157
        • Rekrytering
        • Centrul Medical Melchisedec
      • Focşani, Rumänien, 620117
        • Avslutad
        • CMI Dr. Sarpe Marcel-Claudiu
      • Iași, Rumänien, 700282
        • Avslutad
        • Institutului Regional de Psihiatrie 'Socola' Iasi
      • Iași, Rumänien, 700282
        • Avslutad
        • Institutului Regional de Psihiatrie Socola Iasi 1
      • Iași, Rumänien, 700282
        • Avslutad
        • Institutului Regional de Psihiatrie Socola Iasi 2
      • Oradea, Rumänien, 410169
        • Rekrytering
        • Spitalul Clinic Judetean de Urgenta Oradea
      • Sibiu, Rumänien, 550082
        • Avslutad
        • Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda
      • Sibiu, Rumänien, 550082
        • Avslutad
        • Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda 1
      • Sânpetru, Rumänien, 507190
        • Rekrytering
        • Spitalul de Psihiatrie si Neurologie Brasov
      • Belgrade, Serbien, 11000
        • Aktiv, inte rekryterande
        • University Clinical Center of Serbia
      • Belgrade, Serbien, 11000
        • Aktiv, inte rekryterande
        • University Clinical Hospital Center Dr Dragisa Misovic- Dedi
      • Gornja Toponica, Serbien, 18202
        • Aktiv, inte rekryterande
        • Special Hospital for Psychiatric Diseases Gornja Toponica
      • Kovin, Serbien, 26220
        • Avslutad
        • Special Hospital for Psychiatric Diseases Kovin
      • Novi Kneževac, Serbien, 23330
        • Avslutad
        • Specialized Hospital for Psychiatric Diseases Sveti Vracevi
      • Bratislava, Slovakien, 821 01
        • Avslutad
        • Psychiatricka Ambulancia Mentum S.R.O.
      • Košice, Slovakien, 040 01
        • Rekrytering
        • Univerzitna nemocnica L. Pasteura Kosice
      • Liptovský Mikuláš, Slovakien, 031 23
        • Rekrytering
        • Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
      • Rimavská Sobota, Slovakien, 979 01
        • Rekrytering
        • Psychiatricka Ambulancia Psycholine S.R.O.
      • Svidník, Slovakien, 089 01
        • Rekrytering
        • Psychiatricka Ambulancia Centrum Zdravia R.B.K. S.R.O.
      • Vranov nad Topľou, Slovakien, 093 01
        • Rekrytering
        • Crystal Comfort s.r.o.
      • Barcelona, Spanien, 08036
        • Aktiv, inte rekryterande
        • Hosp Clinic de Barcelona
      • Barcelona, Spanien, 8035
        • Avslutad
        • Hosp Univ Vall D Hebron
      • Barcelona, Spanien, 08025
        • Aktiv, inte rekryterande
        • Institucion Hosp Hestia Palau
      • Bilbao, Spanien, 48013
        • Avslutad
        • Hosp. Univ. de Basurto
      • Collado Villalba, Spanien, 28400
        • Avslutad
        • Hosp. Gral. de Villalba
      • Madrid, Spanien, 28034
        • Avslutad
        • Hospital Ramon y Cajal
      • Madrid, Spanien, 28031
        • Aktiv, inte rekryterande
        • Hosp. Univ. Infanta Leonor
      • Madrid, Spanien, 28046
        • Aktiv, inte rekryterande
        • Hosp. Univ. La Paz
      • Torrevieja, Spanien, 03186
        • Avslutad
        • Hosp. Univ. de Torrevieja
      • Lund, Sverige, 22222
        • Rekrytering
        • ProbarE i Lund AB
      • Mölndal, Sverige, 43153
        • Rekrytering
        • CTC GoCo
      • Stockholm, Sverige, 114 37
        • Rekrytering
        • ProbarE i Stockholm AB
      • Uppsala, Sverige, 75237
        • Rekrytering
        • CTC MTC Uppsala
      • Brno, Tjeckien, 61300
        • Rekrytering
        • Medipa S R O
      • Pilsen, Tjeckien, 301 00
        • Avslutad
        • A Shine S R O
      • Prague, Tjeckien, 10000
        • Rekrytering
        • Clintrial s r o
      • Prague, Tjeckien, 110 00
        • Rekrytering
        • Neuropsychiatrie Petrska sro
      • Prague, Tjeckien, 16000
        • Rekrytering
        • Medical Services Prague S R O
      • Prague, Tjeckien, 12000
        • Avslutad
        • Pragtis S R O
      • Ankara, Turkiet (Türkiye), 06010
        • Rekrytering
        • Gulhane Egitim ve Arastirma Hastanesi
      • Ankara, Turkiet (Türkiye), 06800
        • Avslutad
        • Ankara Bilkent Sehir Hastanesi
      • Ankara, Turkiet (Türkiye), 06620
        • Avslutad
        • Ankara University Medical Faculty
      • Bursa, Turkiet (Türkiye), 16285
        • Avslutad
        • Bursa High Speciality Training and Research Dortcelik Mental Hospital
      • Bursa, Turkiet (Türkiye), 16059
        • Avslutad
        • Uludag Universitesi Tıp Fakultesi Hastanesi
      • Gaziantep, Turkiet (Türkiye), 27580
        • Rekrytering
        • Gaziantep Universitesi Tip Fakultesi
      • Istanbul, Turkiet (Türkiye), 34736
        • Avslutad
        • Erenkoy Mental Hospital
      • Kocaeli, Turkiet (Türkiye), 41001
        • Rekrytering
        • Kocaeli University Medical Faculty
      • Samsun, Turkiet (Türkiye), 55020
        • Rekrytering
        • Liv Hospital
      • Trabzon, Turkiet (Türkiye), 61080
        • Avslutad
        • Karadeniz Teknik University Medical Faculty

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 74 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

Participants in part 1 and direct enrollers to part 2:

  • Meet DSM-5 MDD, without psychotic features based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60
  • Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. An inadequate response is defined as less than (<) 50% reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms other than insomnia present, and overall good tolerability, as assessed by the MGH-ATRQ, and this must include the participant's current antidepressant treatment
  • Is receiving and tolerating well any one of the following SSRI or SNRI for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks
  • Having a major depressive episode of at least moderate severity, as assessed with 17-item Hamilton Depression Rating Scale, implemented through the Structured Interview Guide (SIGH-D) in a blinded manner at screening and must not demonstrate a clinically significant improvement from the beginning to end of screening.

Participants entering after completing part 1:

  • Must have completed Part 1 DB treatment phase
  • Can consistently tolerate study drug (at the end of Part 1), and there is no additional safety risk for the participant if they proceed to Part 2
  • Was able to consistently follow the study procedures in Part 1 as judged by the investigator.
  • Must be medically stable based on clinical laboratory tests

Exclusion Criteria:

  • Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders and uncontrolled Type 1 or Type 2 diabetes mellitus
  • Has a history of narcolepsy and seizures
  • Has current signs/symptoms of hypothyroidism or hyperthyroidism
  • Participants taking thyroid supplementation for antidepressant purposes
  • Has Cushing's disease, Addison's disease, primary amenorrhea, or other evidence of significant medical disorders of the HPA axis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Part 1: Seltorexant

Participants will receive seltorexant orally once daily for 6 weeks during the double-blind (DB) treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant throughout the study.

Seltorexant will be administered orally.

Andra namn:
  • JNJ 42847922

SSRI/SNRI will be administered orally.

Placebo-jämförare: Part 1: Placebo

Participants will receive matching placebo orally once daily for 6 weeks during the DB treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline SSRI/SNRI antidepressant throughout the study.

SSRI/SNRI will be administered orally.

Matching Placebo tablets will be administered orally.

Experimentell: Part 2: Open Label (OL) Seltorexant

All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. In Part 2 open-label phases (induction and stabilization) all participants (newly enrolled direct entry participants and Part 1 roll-over participants) will receive seltorexant orally in addition to their background SSRI/SNRI treatment.

Seltorexant will be administered orally.

Andra namn:
  • JNJ 42847922

SSRI/SNRI will be administered orally.

Experimentell: Part 2: DB Seltorexant

All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phase will receive treatment with seltorexant orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study.

Seltorexant will be administered orally.

Andra namn:
  • JNJ 42847922

SSRI/SNRI will be administered orally.

Placebo-jämförare: Part 2: DB Placebo

All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phases will receive treatment with matching placebo orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study.

SSRI/SNRI will be administered orally.

Matching Placebo tablets will be administered orally.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Part 1: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Day 43
Tidsram: Baseline, Day 43

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline, Day 43
Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Response
Tidsram: Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)

Stable response is defined as a greater than equal to (>=) 50 percent (%) reduction in the MADRS total score for the last 3 consecutive visits of the OL stabilization Phase, as assessed by the site investigator. Time from randomization to the first relapse during the DB maintenance phase in participants who achieve a stable response at the end of OL seltorexant treatment will be reported.

Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Part 1: Change from Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score at Day 43
Tidsram: Baseline, Day 43

MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity.

Baseline, Day 43
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a T-score at Day 43
Tidsram: Baseline, Day 43

The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance.

Baseline, Day 43
Part 1: Change from Baseline in the MADRS-6 Total Score at Day 43
Tidsram: Baseline, Day 43

The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of major depressive disorder (MDD) symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms).

Baseline, Day 43
Part 1: Percentage of Participants with Response on Depressive Symptoms Scale Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total score From Baseline to Day 43
Tidsram: From Baseline to Day 43

Responders are defined as participants with >= 50 percent improvement in the MADRS total score from baseline to Day 43.

From Baseline to Day 43
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (4a) T-score at Day 43
Tidsram: Baseline, Day 43

The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 4-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 4-item form, the lowest possible raw score is 4; the highest possible raw score is 20. Higher overall score indicates more sleep disturbance.

Baseline, Day 43
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (10a) T-score at Day 43
Tidsram: Baseline, Day 43

The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance.

Baseline, Day 43
Part 1: Change from Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score at Day 43
Tidsram: Baseline, Day 43

The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.

Baseline, Day 43
Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Remission
Tidsram: Time from randomization to the first relapse during the maintenance phase (up to 2 years and 10 months)

Stable remission is defined as MADRS total score less than or equal to (<=)10 and CGI-S <= 2 for at least 4 consecutive weeks of the OL stabilization Phase. Time from randomization to the first relapse during the DB maintenance phase in participants who achieve stable remission at the end of the OL seltorexant treatment will be reported.

Time from randomization to the first relapse during the maintenance phase (up to 2 years and 10 months)
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in Sleep Disturbance Using the PROMIS-SD Short Form (8a) T-Score
Tidsram: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)

The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance.

From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in Sleep Disturbance Using the PROMIS-SD Short Form (4a) T-Score
Tidsram: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)

The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 4-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 4-item form, the lowest possible raw score is 4; the highest possible raw score is 20. Higher overall score indicates more sleep disturbance.

From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
Part 2: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (10a) T-score at Day 43
Tidsram: Baseline, Day 43

The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance.

Baseline, Day 43
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in MADRS Total Score
Tidsram: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
Part 2: Change from Baseline to Endpoint of DB Maintenance Phase in PHQ-9 Score
Tidsram: From Baseline (Day 1 in the DB Treatment Maintenance Phase) Until End Point of the DB Maintenance Phase (that is, up to Day 337)

The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the DSM-5 MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.

From Baseline (Day 1 in the DB Treatment Maintenance Phase) Until End Point of the DB Maintenance Phase (that is, up to Day 337)
Change From Baseline to Endpoint of the DB Maintenance Phase in the MADRS-6 score
Tidsram: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)

The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms).

From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
Change from Baseline to Endpoint of the DB Maintenance Phase in the MADRS symptoms other than insomnia MADRS Without Sleep Item (MADRS-WOSI)
Tidsram: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)

MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity.

From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Janssen Research & Development, LLC Clinical Trail, Janssen Research & Development, LLC

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

25 juli 2024

Primärt slutförande (Beräknad)

30 december 2026

Avslutad studie (Beräknad)

4 maj 2029

Studieregistreringsdatum

Först inskickad

15 augusti 2024

Först inskickad som uppfyllde QC-kriterierna

15 augusti 2024

Första postat (Faktisk)

19 augusti 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 42847922MDD3003
  • 42847922MDD3003 (Annan identifierare: Janssen Research & Development, LLC)
  • 2023-509070-36-00 (Registeridentifierare: EUCT number)
  • 2023 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www janssen, com/clinical-trialsitransparency. As noted on this site, requests for access to the study data can be submitted through 'Yale Open Data Access (YODA) Project site at yoda yale.edu

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera